India, Nov. 16 -- Lexeo Therapeutics, Inc. (LXEO) shares are up 11.68 percent, gaining $0.34 to $3.21 on Monday, following positive interim results from its Phase I/II HEROIC-PKP2 study of LX2020, an investigational gene therapy for PKP2 arrhythmogenic cardiomyopathy.
Among seven high-dose patients, LX2020 cut non-sustained ventricular tachycardia by 80 percent and premature ventricular contractions by 44%, with five reporting symptom improvements. The FDA may accept ventricular tachycardia as a surrogate endpoint for accelerated approval. Third-quarter net loss was $38.3 million versus $20.3 million last year, with R&D expenses rising to $34.5 million from $15.7 million.
LXEO is currently trading at $3.21, up from the previous close of $...